Telerehab for Aphasia (TERRA)

失语症远程康复 (TERRA)

• 批准号: 10094379
• 负责人: JULIUS FRIDRIKSSON
• 金额: $ 84.73万
• 依托单位: UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-01 至 2026-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10094379
• 关键词: Acute; Adopted; Affect; Ambulatory Care Facilities; Aphasia; Attitude; Biography; Caring; Case Study; Chronic; Clinic; Clinical Trials; Cognitive; Communication; Data; Databases; Effectiveness; Enzyme-Linked Immunosorbent Assay; Future; Goals; Health; Home; Improve Access; Individual; Inferior; Internet; Language; Language Therapy; Linguistics; Logistics; Medical; Meta-Analysis; Modality; Modeling; Motivation; Names; Neuropsychology; North America; Outcome; Outcome Measure; Participant; Pathologist; Patients; Personal Computers; Persons; Phase; Philadelphia; Physical therapy; Policies; Population; Production; Provider; Quality of life; Randomized; Recovery; Rehabilitation therapy; Research; Semantics; Services; Severities; Source; Speech; Speech Therapy; Stroke; Supervision; Technology; Telemedicine; Testing; Third-Party Payer; Time; Transportation; United States; Work; aphasia recovery; brain health; chronic stroke; comparative efficacy; computerized; cost; disability; executive function; improved; language processing; personalized predictions; phase III trial; phonology; pre-clinical; predicting response; primary endpoint; rehabilitation service; remote therapy; rural area; stroke outcome; stroke recovery; stroke-induced aphasia; synergism; technology validation; telerehabilitation; therapy outcome

Summary: Project 1 It is now commonly accepted that aphasia therapy in chronic stroke is effective for improving language processing, and perhaps to a lesser extent, quality of life. Nevertheless, most persons with chronic aphasia in the United States have very limited access to therapy. Although the reasons for this state of affairs are several, two factors are particularly important: insufficient reimbursement for therapy services and lack of access to local transportation to and from therapy. A way to tackle both of these problems is to provide aphasia therapy at a lower cost and eliminate the need for transportation. Providing aphasia therapy via telemedicine (clinician administered therapy across the internet) will provide cheaper therapy by eliminating the need for a physical facility to provide services and by reducing the need for transportation to and from therapy for either the clinician (home health) or the patient (outpatient clinic). The purpose of Project 1 is to conduct a phase II, non- inferiority trial of telerehab for aphasia therapy (aphasia remote therapy; ART), which will be exclusively administered by a speech-language pathologist. All participants (N=100) will be randomized to receive either telerehab (ART) or in-clinic therapy (I-CT) using the same kind of therapy we are currently using in Project 1. The outcome measure will focus on speech production and combines correct naming and correct words produced per minute during discourse. The primary endpoint is change in the outcome measure at 6 months compared to baseline. The non-inferiority margin will be set so that if ART leads to less than 50% improvement than the improvement following I-CT, it will be considered inferior for therapy delivery. In addition to comparing the difference in outcome for ART and I-CT, we will also explore factors that influence the efficacy of telerehab for aphasia therapy. For this purpose, we use a theoretical framework that is typically used to study the acceptance of and personal attitudes towards telemedicine. Moreover, we will test participants’ cognitive- linguistic status and collect biographical information to study which participants may have difficulty with telerehab and may be poor candidates in a future, phase III trial. If our trial finds that ART is non-inferior to I- CT, it will provide strong motivation to proceed with a phase III trial on a therapy modality that could significantly alter and improve access to aphasia therapy for a population that now is estimated to exceed 2 million individuals in North America. In addition to conducting a very timely clinical trial on ART, the work proposed here will continue to expand our database on aphasia therapy outcome that is being populated in the current phase of Project 1. Accordingly, the synergy between the current and the proposed work in Project 1 will be maintained. Moreover, Project 1 will continue to provide data for Projects 3 and 4 to study brain health in relation to aphasia therapy outcome and neuropsychological models of language, respectively.

项目1